Yuhang Deng
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Yuhang Deng has a total of 42 co-authors. Here are the top co-authors by number of shared publications:
- Chuanbao Zhang
National Center for Clinical Laboratories, Beijing Engineering Research Center of Laboratory Medicine, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, P. R. China
7 shared publications - Weiyan Zhou
National Center for Clinical Laboratories , Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing Hospital/National Center of Gerontology , Beijing , P.R. China
7 shared publications Haijian Zhao
National Center for Clinical Laboratories , Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing Hospital/ National Center of Gerontology , Beijing , P.R. China
4 shared publications- Haijian Zhao
National Center for Clinical Laboratories, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing Hospital, National Center of Gerontology, Beijing, China
3 shared publications Jiangtao Zhang
National Center for Clinical Laboratories , Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing Hospital/ National Center of Gerontology , Beijing , P.R. China
3 shared publicationsJie Zeng
National Center for Clinical Laboratories , Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing Hospital/ National Center of Gerontology , Beijing , P.R. China
3 shared publications
Latest Publications
- Open Access
- 2 February 2026
- Published by American Chemical Society (ACS) in ACS Omega
- Vol. 11 (6) , 9138-9144
Immunocapture-LC-MS/MS Method for Quantification of the Anti-Alzheimer’s Monoclonal Antibody Donanemab in Human and Mice Serum
Monoclonal antibodies hold significant promise for the treatment of Alzheimer’s disease (AD), and donanemab is the latest therapeutic human IgG1 antibody approved for clinical use. The development and pharmacokinetic evaluation of antibody drugs necessitate accurate quantification. Currently, immunoassays are mainly used by clinical trials to measure those antibody drugs for AD. However, immunoassays often face limitations such as cross-reactivity, insufficient specificity, and poor interlaboratory comparability. Therefore, we developed a robust liquid chromatography–tandem mass spectrometry (LC–MS/MS) method incorporating immunoaffinity enrichment for serum donanemab. This LC–MS/MS method can effectively distinguish donanemab from endogenous immunoglobulins in serum and have sufficient sensitivity. This developed LC–MS/MS method involved: (1) immunoaffinity capture and enrichment of serum donanemab and its internal standard using protein G-conjugated magnetic beads; (2) tryptic digestion of the purified antibodies; and (3) targeted quantification of unique signature peptides via LC–MS/MS for quantification. In conclusion, this method demonstrated acceptable performance, including a lower limit of quantification of 0.1 μg/mL, satisfactory precision (total CV < 8%), high accuracy (95–100% recovery), and a wide linear range (0.2–200 μg/mL), and is the first reported LC–MS/MS method for donanemab offering an alternative for therapeutic antibody monitoring of monoclonal antibody drugs.
- 2 February 2026
- Published by American Chemical Society (ACS) in ACS Omega
- Vol. 11 (6) , 9138-9144
Open AccessImmunocapture-LC-MS/MS Method for Quantification of the Anti-Alzheimer’s Monoclonal Antibody Donanemab in Human and Mice Serum
Monoclonal antibodies hold significant promise for the treatment of Alzheimer’s disease (AD), and donanemab is the latest therapeutic human IgG1 antibody approved for clinical use. The development and pharmacokinetic evaluation of antibody drugs necessitate accurate quantification. Currently, immunoassays are mainly used by clinical trials to measure those antibody drugs for AD. However, immunoassays often face limitations such as cross-reactivity, insufficient specificity, and poor interlaboratory comparability. Therefore, we developed a robust liquid chromatography–tandem mass spectrometry (LC–MS/MS) method incorporating immunoaffinity enrichment for serum donanemab. This LC–MS/MS method can effectively distinguish donanemab from endogenous immunoglobulins in serum and have sufficient sensitivity. This developed LC–MS/MS method involved: (1) immunoaffinity capture and enrichment of serum donanemab and its internal standard using protein G-conjugated magnetic beads; (2) tryptic digestion of the purified antibodies; and (3) targeted quantification of unique signature peptides via LC–MS/MS for quantification. In conclusion, this method demonstrated acceptable performance, including a lower limit of quantification of 0.1 μg/mL, satisfactory precision (total CV < 8%), high accuracy (95–100% recovery), and a wide linear range (0.2–200 μg/mL), and is the first reported LC–MS/MS method for donanemab offering an alternative for therapeutic antibody monitoring of monoclonal antibody drugs.
- 1 May 2025
- Published by Walter de Gruyter GmbH in Clinical Chemistry and Laboratory Medicine (CCLM)
- Vol. 63 (9) , 1800-1813
Standardization challenges in antipsychotic drug monitoring: insights from a national survey in Chinese TDM practices
Objectives: Therapeutic drug monitoring (TDM) is critical for optimizing antipsychotic therapy, yet inter-laboratory comparability in China remains poor. Unstandardized practices risk suboptimal dosing and adverse effects, highlighting the need for standardization. This study evaluated TDM practices for six antipsychotics (olanzapine, clozapine, risperidone, quetiapine, aripiprazole, and paliperidone), focusing on inter-laboratory variability, quality control material suitability, and measurement system differences. Methods: Four processed serum samples (two frozen, two lyophilized) containing the six antipsychotic drugs were distributed to over 100 laboratories. The analyses utilized LC-MS/MS, chemiluminescence immunoassays, and HPLC. Sample homogeneity, stability, matrix effects, and method precision, and accuracy were assessed systematically. Results: Significant inter-laboratory variability occurred for six antipsychotics. Only quetiapine met the external quality assessment (EQA) requirements, with inter-laboratory coefficients of variation (CVs) ranging from 12.08 to 15.23 %. Others, especially olanzapine (CVs: 43.48–45.30 %), had poor precision (CVs>15 %). The study revealed that commercial in vitro diagnostic kits generally provided more consistent results compared to laboratory-developed tests. However, even with commercial kits, some drugs, such as aripiprazole, still showed substantial deviations. Lyophilized samples surpassed frozen ones in stability and EQA suitability, which exhibited comparable matrix effects across most assay systems. Conclusions: Urgent standardization of Chinese TDM practices is needed, including harmonized systems and traceable calibrators. While commercial kits enhance result consistency, further efforts are required to harmonize performance across manufacturers. Lyophilized materials are optimal for EQA due to their stability and ease of transport. These findings offer actionable insights to improve the quality and comparability of antipsychotic TDM in clinical practice.
- 1 May 2025
- Published by Walter de Gruyter GmbH in Clinical Chemistry and Laboratory Medicine (CCLM)
- Vol. 63 (9) , 1800-1813
Standardization challenges in antipsychotic drug monitoring: insights from a national survey in Chinese TDM practices
Objectives: Therapeutic drug monitoring (TDM) is critical for optimizing antipsychotic therapy, yet inter-laboratory comparability in China remains poor. Unstandardized practices risk suboptimal dosing and adverse effects, highlighting the need for standardization. This study evaluated TDM practices for six antipsychotics (olanzapine, clozapine, risperidone, quetiapine, aripiprazole, and paliperidone), focusing on inter-laboratory variability, quality control material suitability, and measurement system differences. Methods: Four processed serum samples (two frozen, two lyophilized) containing the six antipsychotic drugs were distributed to over 100 laboratories. The analyses utilized LC-MS/MS, chemiluminescence immunoassays, and HPLC. Sample homogeneity, stability, matrix effects, and method precision, and accuracy were assessed systematically. Results: Significant inter-laboratory variability occurred for six antipsychotics. Only quetiapine met the external quality assessment (EQA) requirements, with inter-laboratory coefficients of variation (CVs) ranging from 12.08 to 15.23 %. Others, especially olanzapine (CVs: 43.48–45.30 %), had poor precision (CVs>15 %). The study revealed that commercial in vitro diagnostic kits generally provided more consistent results compared to laboratory-developed tests. However, even with commercial kits, some drugs, such as aripiprazole, still showed substantial deviations. Lyophilized samples surpassed frozen ones in stability and EQA suitability, which exhibited comparable matrix effects across most assay systems. Conclusions: Urgent standardization of Chinese TDM practices is needed, including harmonized systems and traceable calibrators. While commercial kits enhance result consistency, further efforts are required to harmonize performance across manufacturers. Lyophilized materials are optimal for EQA due to their stability and ease of transport. These findings offer actionable insights to improve the quality and comparability of antipsychotic TDM in clinical practice.
- 29 March 2024
- Published by Walter de Gruyter GmbH in Clinical Chemistry and Laboratory Medicine (CCLM)
- Vol. 62 (11) , 2233-2241
Insight into the status of plasma renin and aldosterone measurement: findings from 526 clinical laboratories in China
Objectives: Accurate measurements of renin and aldosterone levels play an important role in primary aldosteronism screening, which is of great importance in the management and categorization of hypertension. The objective of this study is to investigate the current status of plasma renin and aldosterone measurements in China, which is achieved by analyzing the results of 526 clinical laboratories nationwide for three pooled fresh plasma samples derived from more than 2,000 patients. Methods: Renin and aldosterone in three pooled plasma samples were measured four times in 526 laboratories employing various measurement systems. The inter- and intra-laboratory %CV were calculated and compared. To determine the source of the substantial inter-laboratory %CV, laboratories were categorized according to the measurement systems they are using, and both the inter- and intra-measurement-system %CV were calculated and compared. Results: Regarding renin, the majority of laboratories use four primary commercial immunoassays. However, for aldosterone, in addition to commercial immunoassays, laboratory-developed liquid chromatography-tandem mass spectrometry (LC-MS) methods are also used by laboratories. The median values of intra-laboratory %CVs, intra-measurement-system %CVs, inter-laboratory %CVs, and inter-measurement systems %CVs varied between 1.6 and 2.6 %, 4.6 and 14.9 %, 8.3 and 25.7 %, and 10.0 and 34.4 % for renin, respectively. For aldosterone, these values ranged from 1.4 to 2.2 %, 2.5–14.7 %, 9.9–31.0 %, and 10.0–35.5 %, respectively. Conclusions: The precision within laboratories and measurement systems for plasma renin and aldosterone measurements is satisfactory. However, the comparability between laboratories using different measurement systems remains lacking, indicating the long way to achieve standardization and harmonization for these two analytes.
- 29 March 2024
- Published by Walter de Gruyter GmbH in Clinical Chemistry and Laboratory Medicine (CCLM)
- Vol. 62 (11) , 2233-2241
Insight into the status of plasma renin and aldosterone measurement: findings from 526 clinical laboratories in China
Objectives: Accurate measurements of renin and aldosterone levels play an important role in primary aldosteronism screening, which is of great importance in the management and categorization of hypertension. The objective of this study is to investigate the current status of plasma renin and aldosterone measurements in China, which is achieved by analyzing the results of 526 clinical laboratories nationwide for three pooled fresh plasma samples derived from more than 2,000 patients. Methods: Renin and aldosterone in three pooled plasma samples were measured four times in 526 laboratories employing various measurement systems. The inter- and intra-laboratory %CV were calculated and compared. To determine the source of the substantial inter-laboratory %CV, laboratories were categorized according to the measurement systems they are using, and both the inter- and intra-measurement-system %CV were calculated and compared. Results: Regarding renin, the majority of laboratories use four primary commercial immunoassays. However, for aldosterone, in addition to commercial immunoassays, laboratory-developed liquid chromatography-tandem mass spectrometry (LC-MS) methods are also used by laboratories. The median values of intra-laboratory %CVs, intra-measurement-system %CVs, inter-laboratory %CVs, and inter-measurement systems %CVs varied between 1.6 and 2.6 %, 4.6 and 14.9 %, 8.3 and 25.7 %, and 10.0 and 34.4 % for renin, respectively. For aldosterone, these values ranged from 1.4 to 2.2 %, 2.5–14.7 %, 9.9–31.0 %, and 10.0–35.5 %, respectively. Conclusions: The precision within laboratories and measurement systems for plasma renin and aldosterone measurements is satisfactory. However, the comparability between laboratories using different measurement systems remains lacking, indicating the long way to achieve standardization and harmonization for these two analytes.
- 3 April 2023
- Published by Walter de Gruyter GmbH in Clinical Chemistry and Laboratory Medicine (CCLM)
- Vol. 61 (9) , 1597-1604
Exploration of suitable external quality assessment materials for serum C-peptide measurement
Objectives: To find suitable external quality assessment (EQA) materials for serum C-peptide, we evaluated the commutability of five types of processed materials. Methods: Seventy-four individual serum samples and 12 processed samples including three EQA samples currently in use, frozen human serum pools (FHSP), and three other kinds of processed samples were prepared by dissolving WHO International Standard Reagent for C-peptide (WHO ISR 13/146) in three different matrixes: 0.05 % bovine serum albumin, fetal bovine serum and human serum pools. Samples were analyzed using the isotope dilution liquid chromatography-tandem mass spectrometry (ID-LC-MS/MS) method and six widely used immunoassays. The commutabilities of processed materials were assessed according to the difference in bias approach recommended by the IFCC. And the short- and long-term stability of FHSP samples at different temperatures were also evaluated. Results: Out of the five kinds of processed materials, FHSP samples were commutable on most assays. In contrast, the EQA materials currently in use were only commutable on a few immunoassays. Additionally, processed materials derived from WHO ISR 13/146 were found to be un-commutable on over half of immunoassays. The FHSP samples could be stably stored at 4 and −20 °C for at least 16 days, and at −80 °C for at least 1 year, but at room temperature only for 12 h. Conclusions: With clarified commutability and stability information, the human serum pool samples along with the developed ID-LC-MS/MS method could be used in the EQA program to promote the comparability among laboratories for C-peptide measurement in China.
- 3 April 2023
- Published by Walter de Gruyter GmbH in Clinical Chemistry and Laboratory Medicine (CCLM)
- Vol. 61 (9) , 1597-1604
Exploration of suitable external quality assessment materials for serum C-peptide measurement
Objectives: To find suitable external quality assessment (EQA) materials for serum C-peptide, we evaluated the commutability of five types of processed materials. Methods: Seventy-four individual serum samples and 12 processed samples including three EQA samples currently in use, frozen human serum pools (FHSP), and three other kinds of processed samples were prepared by dissolving WHO International Standard Reagent for C-peptide (WHO ISR 13/146) in three different matrixes: 0.05 % bovine serum albumin, fetal bovine serum and human serum pools. Samples were analyzed using the isotope dilution liquid chromatography-tandem mass spectrometry (ID-LC-MS/MS) method and six widely used immunoassays. The commutabilities of processed materials were assessed according to the difference in bias approach recommended by the IFCC. And the short- and long-term stability of FHSP samples at different temperatures were also evaluated. Results: Out of the five kinds of processed materials, FHSP samples were commutable on most assays. In contrast, the EQA materials currently in use were only commutable on a few immunoassays. Additionally, processed materials derived from WHO ISR 13/146 were found to be un-commutable on over half of immunoassays. The FHSP samples could be stably stored at 4 and −20 °C for at least 16 days, and at −80 °C for at least 1 year, but at room temperature only for 12 h. Conclusions: With clarified commutability and stability information, the human serum pool samples along with the developed ID-LC-MS/MS method could be used in the EQA program to promote the comparability among laboratories for C-peptide measurement in China.
- Open Access
- 24 February 2023
- Published by Annals of Laboratory Medicine in Annals of Laboratory Medicine
- Vol. 43 (4) , 345-354
An Accurate Isotope Dilution Liquid Chromatography-Tandem Mass Spectrometry Method for Serum C-Peptide and Its Use in Harmonization in China
Yuhang Deng, M.D., Chao Zhang, M.D., Jing Wang, M.M., Jie Zeng, M.M., Jiangtao Zhang, M.M., Tianjiao Zhang, M.D., Haijian Zhao, M.M., Weiyan Zhou, M.D., and Chuanbao Zhang, M.D.. Ann Lab Med 2023;43:345-54. https://doi.org/10.3343/alm.2023.43.4.345
- 24 February 2023
- Published by Annals of Laboratory Medicine in Annals of Laboratory Medicine
- Vol. 43 (4) , 345-354
Open AccessAn Accurate Isotope Dilution Liquid Chromatography-Tandem Mass Spectrometry Method for Serum C-Peptide and Its Use in Harmonization in China
Yuhang Deng, M.D., Chao Zhang, M.D., Jing Wang, M.M., Jie Zeng, M.M., Jiangtao Zhang, M.M., Tianjiao Zhang, M.D., Haijian Zhao, M.M., Weiyan Zhou, M.D., and Chuanbao Zhang, M.D.. Ann Lab Med 2023;43:345-54. https://doi.org/10.3343/alm.2023.43.4.345
- 18 February 2023
- Published by SAGE Publications in Annals of Clinical Biochemistry: International Journal of Laboratory Medicine
- Vol. 60 (3) , 199-207
Application of serum pools in insulin harmonization: Commutability and stability
Background: Recalibration using serum pools assigned by higher-order reference methods had been demonstrated to be effective in improving the agreement among insulin immunoassays. To promote the application of serum pools in insulin harmonization, this study analyzed serum pools’ commutability between insulin immunoassays, and their short- and long-term stability at different temperatures. The agreement between commonly used immunoassays was also evaluated. Methods: Insulin in 69 individual serum samples, 10 serum pools, and three EQA samples (lyophilized powder of serum pools) were detected by six widely used immunoassays. The commutability of serum pools and EQA samples was evaluated according to the IFCC-recommended approach. Serum pools’ stability at different temperatures was investigated by placing them at various temperatures for varying lengths of time. Individual serum samples’ results were analyzed using the Bland–Altman and Passing and Bablok regression analyses. Results: Serum pools were commutable among most assays, the EQA samples—lyophilized serum pools—were non-commutable among most assays. Serum pools can be stably stored at −20°C and −80°C for at least one year, but can only be stably stored at room temperature for twenty-four hours. Significant relative differences were observed among assays. Recalibration using serum pools can only improve the assays’ agreement at middle and high insulin levels, but not at low levels. Conclusions: Serum pools were commutable and stable for insulin measurement and can be used in insulin harmonization. The existing EQA materials were non-commutable between most assays, and other EQA materials, such as serum pools, should be studied.
- 18 February 2023
- Published by SAGE Publications in Annals of Clinical Biochemistry: International Journal of Laboratory Medicine
- Vol. 60 (3) , 199-207
Application of serum pools in insulin harmonization: Commutability and stability
Background: Recalibration using serum pools assigned by higher-order reference methods had been demonstrated to be effective in improving the agreement among insulin immunoassays. To promote the application of serum pools in insulin harmonization, this study analyzed serum pools’ commutability between insulin immunoassays, and their short- and long-term stability at different temperatures. The agreement between commonly used immunoassays was also evaluated. Methods: Insulin in 69 individual serum samples, 10 serum pools, and three EQA samples (lyophilized powder of serum pools) were detected by six widely used immunoassays. The commutability of serum pools and EQA samples was evaluated according to the IFCC-recommended approach. Serum pools’ stability at different temperatures was investigated by placing them at various temperatures for varying lengths of time. Individual serum samples’ results were analyzed using the Bland–Altman and Passing and Bablok regression analyses. Results: Serum pools were commutable among most assays, the EQA samples—lyophilized serum pools—were non-commutable among most assays. Serum pools can be stably stored at −20°C and −80°C for at least one year, but can only be stably stored at room temperature for twenty-four hours. Significant relative differences were observed among assays. Recalibration using serum pools can only improve the assays’ agreement at middle and high insulin levels, but not at low levels. Conclusions: Serum pools were commutable and stable for insulin measurement and can be used in insulin harmonization. The existing EQA materials were non-commutable between most assays, and other EQA materials, such as serum pools, should be studied.
- Open Access
- 1 September 2022
- Published by Annals of Laboratory Medicine in Annals of Laboratory Medicine
- Vol. 42 (5) , 575-584
Commutability Assessment of Processed Human Plasma Samples for Normetanephrine and Metanephrine Measurements Based on the Candidate Reference Measurement Procedure
Yuhang Deng, M.D., Qingxiang Liu, M.S., Zhenni Liu, M.D., Haijian Zhao, M.D., Weiyan Zhou, M.D., and Chuanbao Zhang, M.D.. Ann Lab Med 2022;42:575-84. https://doi.org/10.3343/alm.2022.42.5.575
- 1 September 2022
- Published by Annals of Laboratory Medicine in Annals of Laboratory Medicine
- Vol. 42 (5) , 575-584
Open AccessCommutability Assessment of Processed Human Plasma Samples for Normetanephrine and Metanephrine Measurements Based on the Candidate Reference Measurement Procedure
Yuhang Deng, M.D., Qingxiang Liu, M.S., Zhenni Liu, M.D., Haijian Zhao, M.D., Weiyan Zhou, M.D., and Chuanbao Zhang, M.D.. Ann Lab Med 2022;42:575-84. https://doi.org/10.3343/alm.2022.42.5.575
- Open Access
- 1 July 2022
- Published by Annals of Laboratory Medicine in Annals of Laboratory Medicine
- Vol. 42 (4) , 428-437
Current Status of Serum Insulin and C-Peptide Measurement in Clinical Laboratories: Experience from 94 Laboratories in China
Weiyan Zhou , M.D., Yuhang Deng , M.D., Haijian Zhao , M.D., and Chuanbao Zhang , M.D.. Ann Lab Med 2022;42:428-37. https://doi.org/10.3343/alm.2022.42.4.428
- 1 July 2022
- Published by Annals of Laboratory Medicine in Annals of Laboratory Medicine
- Vol. 42 (4) , 428-437
Open AccessCurrent Status of Serum Insulin and C-Peptide Measurement in Clinical Laboratories: Experience from 94 Laboratories in China
Weiyan Zhou , M.D., Yuhang Deng , M.D., Haijian Zhao , M.D., and Chuanbao Zhang , M.D.. Ann Lab Med 2022;42:428-37. https://doi.org/10.3343/alm.2022.42.4.428
- Open Access
- 18 November 2021
- Published by Stanford University Press in Journal of Mass Spectrometry and Advances in the Clinical Lab
- Vol. 22, 81-82
In reply
- 18 November 2021
- Published by Stanford University Press in Journal of Mass Spectrometry and Advances in the Clinical Lab
- Vol. 22, 81-82
Open AccessIn reply